Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism

Archives of Toxicology

Volumn 90, Issue 2, 2016, Pages 291-304

  Wohak, Laura E ^a,b   Krais, Annette M ^a   Kucab, Jill E ^a   Stertmann, Julia ^a   Øvrebø, Steinar ^c   Seidel, Albrecht ^d   Phillips, David H ^a   Arlt, Volker M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^d Prof Dr Gernot Grimmer Foundation   (Germany)

Author keywords

Benzo a pyrene; Carcinogen metabolism; Cytochrome P450; DNA adducts; Tumour suppressor p53

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CYTOCHROME P450 1A1; DIBENZO[A,L]PYRENE; DIBENZ[A,H]ANTHRACENE; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; AHR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CARCINOGEN; CYP1A1 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450 1B1; CYTOCHROME P450 INDUCER; DNA ADDUCT; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TP53 PROTEIN, HUMAN;

ARTICLE; CARCINOGENICITY; COLORECTAL CANCER CELL LINE; CULTURE MEDIUM; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; WESTERN BLOTTING; XENOBIOTIC METABOLISM; CELL SURVIVAL; DNA ADDUCT; DNA DAMAGE; DRUG EFFECTS; DRUG INACTIVATION; GENETICS; HCT 116 CELL LINE; METABOLISM; TOXICITY TESTING;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZO(A)PYRENE; CARCINOGENS; CELL SURVIVAL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1B1; CYTOCHROME P-450 ENZYME INDUCERS; DNA ADDUCTS; DNA DAMAGE; HCT116 CELLS; HUMANS; INACTIVATION, METABOLIC; NAD(P)H DEHYDROGENASE (QUINONE); POLYCYCLIC AROMATIC HYDROCARBONS; RECEPTORS, ARYL HYDROCARBON; TOXICITY TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84958124444     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1409-1     Document Type: Article

References (60)

1. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, Phillips DH (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65:2644–2652
2. Arlt VM, Schmeiser HH, Osborne MR et al (2006) Identification of three major DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine. Int J Cancer 118:2139–2146
3. Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH (2007) Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28:2253–2261
4. Arlt VM, Stiborova M, Henderson CJ, Thiemann M, Frei E, Aimova D, Singh R, Gamboa da Costa G, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29:656–665
5. Baird WM, Hooven LA, Mahadevan B (2005) Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ Mol Mutagen 45:106–114
6. Beier JI, McClain CJ (2010) Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 391:1249–1264
7. Berger AH, Pandolfi PP (2011) Haplo-insufficiency: a driving force in cancer. J Pathol 223(2):137–146
8. Berger AH, Knudson AG, Pandolfi PP (2011) A continuum model for tumour suppression. Nature 476:163–169
9. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269
10. Chang RL, Wood AW, Huang MT, Xie JG, Cui XX, Reuhl KR, Boyd DR, Lin Y, Shih WJ, Balani SK, Yagi H, Jerina DM, Conney AH (2013) Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene. Carcinogenesis 34:2184–2191
11. Crowell SR, Hanson-Drury S, Williams DE, Corley RA (2014) In vitro metabolism of benzo[a]pyrene and dibenzo[def, p]chrysene in rodent and human hepatic microsomes. Toxicol Lett 228:48–55
12. Dendele B, Tekpli X, Hardonniere K, Holme JA, Debure L, Catheline D, Arlt VM, Nagy E, Phillips DH, Ovrebo S, Mollerup S, Poet M, Chevanne M, Rioux V, Dimanche-Boitrel MT, Sergent O, Lagadic-Gossmann D (2014) Protective action of n-3 fatty acids on benzo[a]pyrene-induced apoptosis through the plasma membrane remodeling-dependent NHE1 pathway. Chem Biol Interact 207:41–51
13. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430–432
14. Ford JM (2005) Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Mutat Res 577:195–202
15. Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268–1286
16. Gokmen MR, Cosyns JP, Arlt VM, Stiborova M, Phillips DH, Schmeiser HH, Simmonds MS, Cook HT, Vanherweghem JL, Nortier JL, Lord GM (2013) The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 158:469–477
17. Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V (2013) Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 34:190–198
18. Hamouchene H, Arlt VM, Giddings I, Phillips DH (2011) Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene. BMC Genom 12:333
19. Hockley SL, Arlt VM, Brewer D, Giddings I, Phillips DH (2006) Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2. BMC Genom 7:260
20. Hockley SL, Arlt VM, Brewer D, Te Poele R, Workman P, Giddings I, Phillips DH (2007) AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. Chem Res Toxicol 20:1797–1810
21. Hockley SL, Arlt VM, Jahnke G, Hartwig A, Giddings I, Phillips DH (2008) Identification through microarray gene expression analysis of cellular responses to benzo(a)pyrene and its diol-epoxide that are dependent or independent of p53. Carcinogenesis 29:202–210
22. Hu DG, Rogers A, Mackenzie PI (2014) Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol 85:887–897
23. IARC (2010) Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC Monogr Eval Carcinog Risk Hum 92:1–853
24. Kaeser MD, Iggo RD (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99:95–100
25. Karle JM, Mah HD, Jerina DM, Yagi H (1977) Synthesis of dihydrodiols from chrysene and dibenz[a,h]anthracene. Tetrahedron Lett 18:4021–4024
26. Kucab JE, Phillips DH, Arlt VM (2010) Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J 277:2567–2583
27. Kucab JE, Phillips DH, Arlt VM (2012) Metabolic activation of diesel exhaust carcinogens in primary and immortalized human TP53 knock-in (Hupki) mouse embryo fibroblasts. Environ Mol Mutagen 53:207–217
28. Labib S, Yauk C, Williams A, Arlt VM, Phillips DH, White PA, Halappanavar S (2012) Subchronic oral exposure to benzo(a)pyrene leads to distinct transcriptomic changes in the lungs that are related to carcinogenesis. Toxicol Sci 129:213–224
29. Langie SA, Knaapen AM, Brauers KJ, van Berlo D, van Schooten FJ, Godschalk RW (2006) Development and validation of a modified comet assay to phenotypically assess nucleotide excision repair. Mutagenesis 21:153–158
30. Laptenko O, Beckerman R, Freulich E, Prives C (2011) p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc Natl Acad Sci USA 108:10385–10390
31. Lee HM, Harvey RG (1980) Synthesis of biologically active metabolites of dibenz[a,h]anthrance. J Org Chem 45:588–592
32. Lemieux CL, Douglas GR, Gingerich J, Phonethepswath S, Torous DK, Dertinger SD, Phillips DH, Arlt VM, White PA (2011) Simultaneous measurement of benzo[a]pyrene-induced Pig-a and lacZ mutations, micronuclei and dna adducts in muta(TM) mouse. Environ Mol Mutagen 52:756–765
33. Leung T, Rajendran R, Singh S, Garva R, Krstic-Demonacos M, Demonacos C (2013) Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells. Breast Cancer Res 15:R107
34. Luch A, Baird WM (2005) Metabolic activation and detoxification of polycyclic aromatic hydrocarbons. Imperial College Press, London, pp p19–p96
35. Luch A, Glatt HR, Platt KL, Oesch F, Seidel A (1994) Synthesis and mutagenicity of diastereomeric fjord-region 11,12-dihydrodiol 13,14-epoxides of dibenzo[a,l]pyrene. Carcinogenesis 15:2507–2516
36. Lynch CJ, Milner J (2006) Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 25:3463–3470
37. Maddocks OD, Vousden KH (2011) Metabolic regulation by p53. J Mol Med 89:237–245
38. Malik AI, Williams A, Lemieux CL, White PA, Yauk CL (2012) Hepatic mRNA, microRNA, and miR-34a-target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation. Environ Mol Mutagen 53:10–21
39. Malik AI, Rowan-Carroll A, Williams A, Lemieux CL, Long AS, Arlt VM, Phillips DH, White PA, Yauk CL (2013) Hepatic genotoxicity and toxicogenomic responses in MutaMouse males treated with dibenz[a,h]anthracene. Mutagenesis 28:543–554
40. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev 9:724–737
41. Odell AF, Odell LR, Askham JM, Alogheli H, Ponnambalam S, Hollstein M (2013) A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem 288:16704–16714
42. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008
43. Phillips DH (2005) Macromolecular adducts as biomarkers of human exposure to polycyclic aromatic hydrocarbons. Imperial College Press, London, pp p137–p169
44. Phillips DH, Arlt VM (2007) The 32P-postlabeling assay for DNA adducts. Nat Protocol 2:2772–2781
45. Platt KL, Oesch F (1981) Reductive cyclization of keto acids to polycyclic aromatic hydrocarbons by hydroiodic acid-red phosphorus. J Org Chem 46:2601–2603
46. Platt KL, Oesch F (1983) Efficient synthesis of non-K-region trans-dihydro diols of polycyclic aromatic hydrocarbons from o-quinones and catechols. J Org Chem 48:265–268
47. Santarosa M, Ashworth A (2004) Haploinsufficiency for tumour suppressor genes: when you don’t need to go all the way. Biochim Biophys Acta 1654:105–122
48. Schmeiser HH, Nortier JL, Singh R, da Costa GG, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM (2014) Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 135:502–507
49. Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6:44–55
50. Siddens LK, Larkin A, Krueger SK, Bradfield CA, Waters KM, Tilton SC, Pereira CB, Lohr CV, Arlt VM, Phillips DH, Williams DE, Baird WM (2012) Polycyclic aromatic hydrocarbons as skin carcinogens: comparison of benzo[a]pyrene, dibenzo[def, p]chrysene and three environmental mixtures in the FVB/N mouse. Toxicol Appl Pharmacol 264:377–386
51. Simoes ML, Hockley SL, Schwerdtle T, da Costa GG, Schmeiser HH, Phillips DH, Arlt VM (2008) Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Toxicol Appl Pharmacol 232:86–98
52. Song H, Hollstein M, Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573–580
53. Stiborova M, Martinek V, Svobodova M, Sistkova J, Dvorak Z, Ulrichova J, Simanek V, Frei E, Schmeiser HH, Phillips DH, Arlt VM (2010) Mechanisms of the different DNA adduct forming potentials of the urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone. Chem Res Toxicol 23:1192–1201
54. Stiborova M, Frei E, Arlt VM, Schmeiser HH (2014) Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica 44:135–145
55. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106:3964–3969
56. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657–4667
57. Wang T, Gavin HM, Arlt VM, Lawrence BP, Fenton SE, Medina D, Vorderstrasse BA (2011) Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors. Int J Cancer 128:1509–1523
58. Wei QX, Odell AF, van der Hoeven F, Hollstein M (2011) Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle 10:1261–1270
59. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev 9:95–107
60. Yagi H, Thakker DR, Hernandez O, Koreeda M, Jerina DM (1977) Synthesis and reactions of the highly mutagenic 7,8-diol 9,10-epoxides of the carcinogen benzo[a]pyrene. J Am Chem Soc 99:1604–1611